• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.

作者信息

Thakare Sayali, Gandhi Chintan, Modi Tulsi, Bose Sreyashi, Deb Satarupa, Saxena Nikhil, Katyal Abhinav, Patil Ankita, Patil Sunil, Pajai Atim, Bajpai Divya, Jamale Tukaram

机构信息

Department of Nephrology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, India.

出版信息

Kidney Int Rep. 2021 Jan;6(1):206-210. doi: 10.1016/j.ekir.2020.10.005. Epub 2020 Oct 10.

DOI:10.1016/j.ekir.2020.10.005
PMID:33073066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7547837/
Abstract
摘要

相似文献

1
Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.瑞德西韦在急性肾损伤或慢性肾脏病患者中的安全性。
Kidney Int Rep. 2021 Jan;6(1):206-210. doi: 10.1016/j.ekir.2020.10.005. Epub 2020 Oct 10.
2
Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).一项前瞻性、开放性、探索性、随机、单中心比较研究的方案和基线数据，旨在确定各种静脉铁制剂对慢性肾脏病（IRON-CKD）患者氧化应激和肾损伤标志物的影响。
Trials. 2019 Apr 4;20(1):194. doi: 10.1186/s13063-019-3291-x.
3
Chronic progression of cardiac surgery associated acute kidney injury: Intermediary role of acute kidney disease.心脏手术相关急性肾损伤的慢性进展：急性肾疾病的中间作用。
J Thorac Cardiovasc Surg. 2021 Feb;161(2):681-688.e3. doi: 10.1016/j.jtcvs.2019.10.101. Epub 2019 Nov 6.
4
Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention.对比剂诱导的急性肾损伤与行急诊经皮冠状动脉介入治疗的慢性肾脏病急性冠状动脉综合征患者长期心血管事件的相关性。
Int J Cardiol. 2014 Jun 1;174(1):57-63. doi: 10.1016/j.ijcard.2014.03.146. Epub 2014 Mar 28.
5
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.瑞德西韦治疗 2019 年冠状病毒引起的肝脏疾病。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2835-2836. doi: 10.1016/j.cgh.2020.07.050. Epub 2020 Jul 25.
6
The risk of chronic kidney disease and mortality are increased after community-acquired acute kidney injury.社区获得性急性肾损伤后，慢性肾脏病风险和死亡率会增加。
Kidney Int. 2016 Nov;90(5):1090-1099. doi: 10.1016/j.kint.2016.07.018. Epub 2016 Sep 19.
7
Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction.急性肾损伤和慢性肾脏病与急性心肌梗死患者的治疗过程和长期结局的关系。
Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):43-50. doi: 10.1093/ehjqcco/qcx020.
8
Association between Chronic Kidney Disease or Acute Kidney Injury and Clinical Outcomes in COVID-19 Patients.慢性肾脏病或急性肾损伤与 COVID-19 患者临床结局的关联。
J Korean Med Sci. 2020 Dec 28;35(50):e434. doi: 10.3346/jkms.2020.35.e434.
9
Risk factors and safe contrast volume thresholds for postcontrast acute kidney injury after peripheral vascular interventions.外周血管介入术后对比剂急性肾损伤的危险因素和安全对比剂容量阈值。
J Vasc Surg. 2020 Aug;72(2):603-610.e1. doi: 10.1016/j.jvs.2019.09.059. Epub 2019 Dec 13.
10
Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.重组α-klotho可能对急性至慢性肾病进展和尿毒症性心肌病具有预防和治疗作用。
Kidney Int. 2017 May;91(5):1104-1114. doi: 10.1016/j.kint.2016.10.034. Epub 2017 Jan 25.

引用本文的文献

1
Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review.瑞德西韦在成人实体器官移植受者中的疗效和安全性：一项范围综述。
Pharmaceuticals (Basel). 2024 Jun 11;17(6):765. doi: 10.3390/ph17060765.
2
A narrative review on adverse drug reactions of COVID-19 treatments on the kidney.关于新冠病毒疾病治疗药物对肾脏不良反应的叙述性综述。
Open Med (Wars). 2024 Mar 15;19(1):20230867. doi: 10.1515/med-2023-0867. eCollection 2024.
3
Remdesivir: treatment of COVID-19 in special populations.瑞德西韦：特殊人群中新型冠状病毒肺炎的治疗
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3829-3855. doi: 10.1007/s00210-023-02927-2. Epub 2024 Jan 5.
4
Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study.真实世界中 COVID-19 住院患者（包括弱势群体）应用瑞德西韦的药物不良反应：一项回顾性多中心研究。
J Korean Med Sci. 2023 Nov 13;38(44):e346. doi: 10.3346/jkms.2023.38.e346.
5
Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis.瑞德西韦治疗腹膜透析患者严重 COVID-19 感染。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231200386. doi: 10.1177/23247096231200386.
6
Remdesivir Use in the Real-World Setting: An Overview of Available Evidence.瑞德西韦在真实世界环境中的应用：现有证据概述。
Viruses. 2023 May 14;15(5):1167. doi: 10.3390/v15051167.
7
Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.通过数字滴度聚合酶链反应（DDPCR）进行系列病毒载量分析，以评估FNC治疗轻度新型冠状病毒肺炎（COVID-19）病例的疗效和安全性。
Front Med (Lausanne). 2023 Mar 14;10:1143485. doi: 10.3389/fmed.2023.1143485. eCollection 2023.
8
Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?你的门诊病人患有 2019 年冠状病毒病：在当前严重急性呼吸综合征冠状病毒 2 变异株流行的情况下，有哪些治疗选择？
Clin Infect Dis. 2023 Jul 5;77(1):32-37. doi: 10.1093/cid/ciad178.
9
Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review.一名新冠肺炎患者出现与瑞德西韦相关的急性肝衰竭：病例报告及文献综述
Cureus. 2023 Jan 26;15(1):e34221. doi: 10.7759/cureus.34221. eCollection 2023 Jan.
10
Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.瑞德西韦对 COVID-19 合并肾功能受损住院患者不良肾脏结局的影响。
PLoS One. 2023 Feb 27;18(2):e0279765. doi: 10.1371/journal.pone.0279765. eCollection 2023.

本文引用的文献

1
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.瑞德西韦用于急性或慢性肾脏病合并新型冠状病毒肺炎患者的研究
J Am Soc Nephrol. 2020 Jul;31(7):1384-1386. doi: 10.1681/ASN.2020050589. Epub 2020 Jun 8.
2
Presentation and Outcomes of Patients with ESKD and COVID-19.终末期肾病患者合并 COVID-19 的表现和结局。
J Am Soc Nephrol. 2020 Jul;31(7):1409-1415. doi: 10.1681/ASN.2020040470. Epub 2020 May 28.
3
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
4
Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.血液透析患者中磺丁基醚-β-环糊精（SBECD）的药代动力学。
Nephrol Dial Transplant. 2012 Mar;27(3):1207-12. doi: 10.1093/ndt/gfr472. Epub 2011 Aug 24.
5
Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).磺丁基醚-β-环糊精（SBECD）的基础和临床药理学评价。
J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109.